ArticleEuropean journal of medical research2025
Survival analysis of metachronous bilateral ectopic breast cancer utilizing the SEER database and the pioneering construction of a nomogram model.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bilateral Primary Breast Cancer: Current Evidence and Future Perspectives.Breast cancer (Dove Medical Press) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionMetachronous bilateral ectopic breast cancer (MBEBC) is clinically rare, but the incidence has been increasing in recent years and no clear therapeutic guidance or prognostic assessment is available.
methodsData on MBEBC patients from the Surveillance, Epidemiology, and End Results (SEER) database were gathered and randomly split into a training set and a validation set at a 7:3 ratio. Independent prognostic risk factors were identified through both univariate and multivariate analyses, and a nomogram was constructed based on these factors to predict survival outcomes.
resultsFrom the SEER database, we collected data on a total of 8240 patients spanning the years 2005-2015. These patients were then randomly divided into a training set (5768) and a validation set (2472) for analysis. The clinicopathological features indicated that Grade 2 tumors were the most prevalent, with invasive ductal carcinoma comprising 71.2% of the cases. Additionally, the majority of MBEBC patients were classified as N0, and only a small fraction (4.2%) exhibited distant metastases. A multivariate COX regression model was developed to identify independent prognostic risk factors for patients whose first and second tumors were both invasive ductal carcinomas, as well as those with more extensive pathological types. Nomograms were also constructed for survival prediction of overall survival (OS) and breast cancer-special survival (BCSS) at 3, 5, and 10 years. Receiver operating characteristic (ROC) curves were plotted and area under the curve (AUC) values were calculated. The AUC was greater than 0.7 in all models, with a 10-year OS of 78.0 (76.0-80.0) and a BCSS of 77.6 (76.0-79.3) in all patients. The calibration curves and decision curve analysis (DCA) demonstrate that the nomogram possesses strong clinical predictive capability and high predictive accuracy.
conclusionThis study detailed the clinicopathological characteristics of patients with the clinically rare MBEBC and identified independent prognostic risk factors across various pathology types. Additionally, a nomogram was developed for individualized prediction of patients' BCSS and OS, offering a new adjunctive tool for the clinical management of MBEBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.